Incyte Genomics financials
$123.20−1.30%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.14B | $4.24B | $3.70B | $3.39B | $2.99B | $2.67B | $2.16B | $1.88B | $1.54B | $1.11B |
| Gross profit | $4.77B | $3.93B | $3.44B | $3.19B | $2.84B | $2.54B | $2.04B | $1.79B | $1.46B | $1.05B |
| Gross margin | 92.8% | 92.6% | 93.1% | 93.9% | 94.9% | 95.1% | 94.7% | 95.0% | 94.8% | 94.7% |
| Operating income | $1.51B | $61.4M | $620.5M | $579.4M | $585.8M | -$263.7M | $402.0M | $129.2M | -$243.4M | $145.0M |
| Net income | $1.29B | $32.6M | $597.6M | $340.7M | $948.6M | -$295.7M | $446.9M | $109.5M | -$313.1M | $104.2M |
| Net margin | 25.0% | 0.8% | 16.2% | 10.0% | 31.8% | −11.1% | 20.7% | 5.8% | −20.4% | 9.4% |
| Diluted EPS | $6.41 | $0.15 | $2.65 | $1.52 | $4.27 | $-1.36 | $2.05 | $0.51 | $-1.53 | $0.54 |
| EBITDA | $1.44B | $150.6M | $708.8M | $659.4M | $658.4M | -$188.5M | $476.2M | $210.4M | -$183.5M | $220.8M |
| Operating cash flow | $1.41B | $335.3M | $496.5M | $969.9M | $734.7M | -$148.0M | $691.0M | $310.1M | -$100.7M | $287.3M |
| Free cash flow | $1.35B | $249.1M | $464.0M | $892.1M | $553.7M | -$335.4M | $612.9M | $236.6M | -$211.7M | $167.1M |
| Diluted shares | 200.7M | 210.5M | 225.9M | 224.0M | 222.1M | 218.1M | 217.7M | 215.6M | 204.6M | 194.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.10B | $1.69B | $3.21B | $2.95B | $2.06B | $1.51B |
| Short-term investments | $482.8M | $470.3M | $442.7M | $287.5M | $290.8M | $288.4M |
| Total debt | $34.7M | $38.0M | $32.6M | $33.3M | $34.3M | $34.9M |
| Total assets | $6.96B | $5.44B | $6.78B | $5.84B | $4.93B | $3.56B |
| Total liabilities | $1.79B | $2.00B | $1.59B | $1.47B | $1.16B | $949.6M |
| Shareholders' equity | $5.17B | $3.45B | $5.19B | $4.37B | $3.77B | $2.61B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology